CA-PEGASUS-TECH
10.3.2021 13:02:13 CET | Business Wire | Press release
Pegasus Tech Ventures (“Pegasus”), a global venture capital firm based in Silicon Valley, announced a partnership with Japan’s television shopping giant Japanet Holdings (“Japanet”) to establish a $50 million corporate venture capital fund to invest in innovative startups around the globe.
Japanet, headquartered in Nagasaki, Japan, is well-known for its home shopping services and now is expanding into other business sectors. The company recently started a new project to build “Stadium City” in Nagasaki, Japan, which will open in 2024. Centered on a sports stadium, the project includes the development of mixed-use facilities such as business offices, retail stores, hotels, and live event arenas, aiming to make it a Nagasaki landmark that will revitalize the local and regional community. Japanet is also committed to the enrichment of elderly life and to providing educational support for children around the globe.
Through the fund with Pegasus, Japanet aims to create value by funding new ideas and collaborating with startups that develop innovative technologies. The fund plans to invest in Silicon Valley and other parts of North America, as well as in Israel, Europe and Asia.
“We at Japanet Group would like to find high-potential startups with talented entrepreneurs and help them succeed and contribute real value to the world. Using a venture fund, we would like to find cutting edge startup technologies that we can use in the Nagasaki 'Stadium City' project, so that we can provide new services, such as child education, elder care, hospitality, and other services that can help with the betterment of people’s lives,” said Akito Takata, President and CEO of Japanet.
"We will leverage our global network to introduce Japanet to top-tier startups,” said Anis Uzzaman, Founder and CEO of Pegasus Tech Ventures. “By making the connection, both the startups and Japanet benefit. Our goal is to create a global innovation platform that supports the growth of our portfolio companies and the success of our corporate partners.”
Pegasus will deploy its team in Silicon Valley and in 15 other regions around the world to find the best startups and connect them with Japanet and Pegasus’ extensive network of corporate partners.
Pegasus has established venture investment funds with over 35 global corporations, including Aisin Seiki, Sojitz Corporation, SEGA SAMMY HOLDINGS, Sunny Health, CAC Holdings Corporation, Teijin Limited, Infocom Corporation, Innotech Corporation, and ASUS, among others.
About Japanet Holdings Co., Ltd.
Based on a corporate vision, "The joy of living now," Japanet operates a home shopping business, as well as a major sports related business designed to revitalize the local and regional community. In order to enrich the "now," Japanet is also working to enhance healthcare services and to address other social issues, such as educational support for children around the world, and support for disaster-stricken areas. For more information, please visit the website https://corporate.japanet.co.jp/ .
About Pegasus Tech Ventures
Pegasus Tech Ventures is a global venture capital firm based in Silicon Valley with $1.5 Billion in Assets Under Management. Pegasus offers intellectual and financial capital to emerging technology companies around the world. In addition to offering institutional investors a top-tier venture capital investment approach, Pegasus also offers a unique Venture Capital-as-a-Service (VCaaS) model for large, global corporations that wish to partner with cutting-edge technology startups. Some of the 35+ corporate partners that have signed up to work with Pegasus include ASUS, Aisin, SEGA, Sojitz, and Omron. These corporations are able to have access to 180+ Pegasus portfolio companies such as SpaceX, 23andMe, SoFi, Bird, Color, App Annie, and many more. To learn more, visit www.pegasustechventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom